A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

Dapagliflozin is a sodium–glucose co-transporter 2 inhibitor in development for the treatment of type 2 diabetes mellitus. A semi-mechanistic population pharmacokinetic (PK) model was developed for dapagliflozin and its inactive metabolite dapagliflozin 3-O-glucuronide (D3OG) with emphasis on renal...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: van der Walt, J-S, Hong, Y, Zhang, L, Pfister, M, Boulton, D W, Karlsson, M O
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2013
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3674329/
https://ncbi.nlm.nih.gov/pubmed/23887724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/psp.2013.20
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller